Ironwood Pharma (IRWD) Misses Q2 EPS by 12c; Reiterates Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand
August 4, 2022 7:00 AM EDTLINZESS (Iinaclotide) EUTRx prescription demand growth in Q2 2022 increased 9% year-over-year
GAAP net income of $37 million and adjusted EBITDA of $56 million; ended Q2 2022 with $504 million in cash and cash equivalents
Completes Board of Directors authorized share repurchase program; repays remaining principal amount of the 2022 Convertible Notes in cash
Reiterates 2022 guidance of U.S. LINZESS net sales growth of low single digits %, total Ironwood revenue of $420 to $430 million and adjusted EBITDA of >$250 million
BOSTON--(BUSINESS... More
